ArticleVaccine2009
A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.
Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Recombinant Human Lactoferrin Reduces Inflammation and Increases Fluoroquinolone Penetration to Primary Granulomas During Mycobacterial Infection of C57Bl/6 Mice.Archivum immunologiae et therapiae experimentalis · 2022Article
- BCG and BCGΔBCG1419c protect type 2 diabetic mice against tuberculosis via different participation of T and B lymphocytes, dendritic cells and pro-inflammatory cytokines.NPJ vaccines · 2020Article
- The pathogenesis of post-primary tuberculosis. A game changer for vaccine development.Tuberculosis (Edinburgh, Scotland) · 2019Review
- Immunogenicity of heparin-binding hemagglutinin expressed byIranian journal of basic medical sciences · 2018Article
- Lactoferrin: Balancing Ups and Downs of Inflammation Due to Microbial Infections.International journal of molecular sciences · 2017Review
- Oral recombinant human or mouse lactoferrin reduces Mycobacterium tuberculosis TDM induced granulomatous lung pathology.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2017Article
- Lactoferrin in a Context of Inflammation-Induced Pathology.Frontiers in immunology · 2017Review
- Recombinant human lactoferrin modulates human PBMC derived macrophage responses to BCG and LPS.Tuberculosis (Edinburgh, Scotland) · 2016Article
- Pulmonary Tuberculosis in Humanized Mice Infected with HIV-1.Scientific reports · 2016Article
- CHO expressed recombinant human lactoferrin as an adjuvant for BCG.International journal of immunopathology and pharmacology · 2015Article
- Effects of CHO-expressed recombinant lactoferrins on mouse dendritic cell presentation and function.Innate immunity · 2015Article
- Post-Spaceflight (STS-135) Mouse Splenocytes Demonstrate Altered Activation Properties and Surface Molecule Expression.PloS one · 2015Article
- Lactoferrin: A Modulator for Immunity against Tuberculosis Related Granulomatous Pathology.Mediators of inflammation · 2015Review
- The effect of carbohydrate moiety structure on the immunoregulatory activity of lactoferrin in vitro.Cellular & molecular biology letters · 2014Article
- Novel recombinant human lactoferrin: differential activation of oxidative stress related gene expression.Journal of biotechnology · 2013Article
- Lactoferrin restrains allergen-induced pleurisy in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2012Article
- OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.The Journal of infectious diseases · 2012Article
- Influence of oral lactoferrin on Mycobacterium tuberculosis induced immunopathology.Tuberculosis (Edinburgh, Scotland) · 2011Article
- Comparing efficacy of BCG/lactoferrin primary vaccination versus booster regimen.Tuberculosis (Edinburgh, Scotland) · 2011Article
- Lactoferrin Augmentation of the BCG Vaccine Leads to Increased Pulmonary Integrity.Tuberculosis research and treatment · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Lactoferrin, an iron binding glycoprotein, possesses multiple immune modulatory activities, including the ability to promote antigen specific cell-mediated immunity. Previous studies showed that adding bovine lactoferrin to the BCG vaccine (an attenuated strain of Mycobacterium bovis Bacillus Calmette Guerin) resulted in increased host protective responses upon subsequent challenge with virulent Erdman Mycobacterium tuberculosis (MTB) in mice. The studies outlined here investigate utility of a novel recombinant human lactoferrin to enhance the BCG vaccine and protect against alveolar injury during experimental MTB infection in mice. Sialylated and non-sialylated forms of the recombinant human lactoferrin (rhLF), glycoengineered in yeast (Pichia pastoris) and expressing humanized N-glycosylation patterns, were examined for their ability to enhance efficacy of the BCG vaccine in a murine TB model system. Results indicated that the sialylated form of the recombinant human lactoferrin generated increased antigen specific recall responses to BCG antigens. Furthermore, augmented protection was demonstrated using the sialylated lactoferrin adjuvant with BCG, resulting in significant reduction in associated pathology following challenge with virulent organisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.